Target intelligence / Profile preview

Non-heme dietary absorption pathway

01

Overview

The Non-heme dietary absorption pathway refers to the molecular and cellular mechanisms by which non-heme iron, predominantly from plant-based foods, is absorbed in the small intestine. This process mainly occurs in the duodenum and involves several key steps: non-heme iron (mostly ferric, Fe³⁺) is first reduced to ferrous iron (Fe²⁺) on the enterocyte surface by a ferric reductase enzyme, duodenal cytochrome B (Dcytb). The reduced ferrous iron is then transported into enterocytes via the divalent metal transporter 1 (DMT1). Inside the cell, iron can be stored in ferritin or exported to the bloodstream via ferroportin. The efficiency of non-heme iron absorption is influenced by dietary enhancers (such as vitamin C, which reduces ferric to ferrous iron and forms soluble complexes) and inhibitors (such as phytates, polyphenols, calcium, and certain proteins)[1][3][4][5]. The pathway is regulated by systemic iron requirements and the peptide hormone hepcidin, which modulates iron transporter availability and activity. Note: If you are searching for a specific protein or molecular target within this pathway, such as "Divalent metal transporter 1 (DMT1)", "Duodenal cytochrome B (Dcytb)", or "Ferroportin (IREG1)", those would be canonical therapeutic or molecular targets. The name "Non-heme dietary absorption pathway" is overly broad and best classified as a physiological process, not a molecule or specific target[1][4].

Other names
Non-heme iron absorption pathwayNonheme iron uptakeNon-haem iron transportIntestinal non-heme iron absorption
02

Mechanism of action

Enhancement of absorption (by reducing agents like vitamin C); competitive inhibition (by other divalent metals, phytates, polyphenols)

03

Biological functions

Iron absorptionDietary mineral homeostasisCellular iron metabolism
04

Disease associations

Iron deficiency anemiaIron overload disorders (secondary, if absorption is misregulated)
05

Safety considerations

Excessive absorption increases risk of iron overload, especially in disorders like hereditary hemochromatosisabsorption inhibition may exacerbate or contribute to iron deficiency
06

Interacting drugs

Iron supplements (such as ferrous sulfate)

1 more in the full profile.

07

Biomarkers

Serum ferritinserum irontransferrin saturation (for monitoring iron status)

Beyond the preview

Go deeper on Non-heme dietary absorption pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Non-heme dietary absorption pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call